These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 38473357)

  • 41. Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma.
    Jiang Z; Zhang W; Sha G; Wang D; Tang D
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pancreatic Exocrine Insufficiency and the Gut Microbiome in Pancreatic Cancer: A Target for Future Diagnostic Tests and Therapies?
    Halle-Smith JM; Hall LA; Powell-Brett SF; Merali N; Frampton AE; Beggs AD; Moss P; Roberts KJ
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Associations between genetically predicted levels of blood metabolites and pancreatic cancer risk.
    Zhong H; Liu S; Zhu J; Wu L
    Int J Cancer; 2023 Jul; 153(1):103-110. PubMed ID: 36757187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
    Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
    Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mendes I; Vale N
    Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression.
    Takahashi R; Macchini M; Sunagawa M; Jiang Z; Tanaka T; Valenti G; Renz BW; White RA; Hayakawa Y; Westphalen CB; Tailor Y; Iuga AC; Gonda TA; Genkinger J; Olive KP; Wang TC
    Gut; 2021 Feb; 70(2):330-341. PubMed ID: 32393543
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
    Canel M; Sławińska AD; Lonergan DW; Kallor AA; Upstill-Goddard R; Davidson C; von Kriegsheim A; Biankin AV; Byron A; Alfaro J; Serrels A
    Gut; 2023 Dec; 73(1):131-155. PubMed ID: 36977556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer.
    Yousuf S; Qiu M; Voith von Voithenberg L; Hulkkonen J; Macinkovic I; Schulz AR; Hartmann D; Mueller F; Mijatovic M; Ibberson D; AlHalabi KT; Hetzer J; Anders S; Brüne B; Mei HE; Imbusch CD; Brors B; Heikenwälder M; Gaida MM; Büchler MW; Weigert A; Hackert T; Roth S
    Gastroenterology; 2023 Oct; 165(4):891-908.e14. PubMed ID: 37263303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma.
    Chang DZ; Ma Y; Ji B; Wang H; Deng D; Liu Y; Abbruzzese JL; Liu YJ; Logsdon CD; Hwu P
    Clin Cancer Res; 2011 Nov; 17(22):7015-23. PubMed ID: 21976550
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
    Graziano V; Dannhorn A; Hulme H; Williamson K; Buckley H; Karim SA; Wilson M; Lee SY; Kaistha BP; Islam S; Thaventhiran JED; Richards FM; Goodwin R; Brais R; Morton JP; Dovedi SJ; Schuller AG; Eyles J; Jodrell DI
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Highly accurate diagnosis of pancreatic cancer by integrative modeling using gut microbiome and exposome data.
    Zhang Y; Zhang H; Liu B; Ning K
    iScience; 2024 Mar; 27(3):109294. PubMed ID: 38450156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
    Luna J; Boni J; Cuatrecasas M; Bofill-De Ros X; Núñez-Manchón E; Gironella M; Vaquero EC; Arbones ML; de la Luna S; Fillat C
    Gut; 2019 Aug; 68(8):1465-1476. PubMed ID: 30343272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of the endocrine organ-like tumor hypothesis of cancer cachexia in pancreatic ductal adenocarcinoma.
    Yu YC; Ahmed A; Lai HC; Cheng WC; Yang JC; Chang WC; Chen LM; Shan YS; Ma WL
    Front Oncol; 2022; 12():1057930. PubMed ID: 36465353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
    Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
    Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.
    Okabe J; Kodama T; Sato Y; Shigeno S; Matsumae T; Daiku K; Sato K; Yoshioka T; Shigekawa M; Higashiguchi M; Kobayashi S; Hikita H; Tatsumi T; Okamoto T; Satoh T; Eguchi H; Akira S; Takehara T
    J Exp Clin Cancer Res; 2023 Oct; 42(1):262. PubMed ID: 37814340
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of microbiome in pancreatic cancer.
    Li JJ; Zhu M; Kashyap PC; Chia N; Tran NH; McWilliams RR; Bekaii-Saab TS; Ma WW
    Cancer Metastasis Rev; 2021 Sep; 40(3):777-789. PubMed ID: 34455517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ketogenic Diets in Pancreatic Cancer and Associated Cachexia: Cellular Mechanisms and Clinical Perspectives.
    Cortez NE; Mackenzie GG
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bile Microbiome Signatures Associated with Pancreatic Ductal Adenocarcinoma Compared to Benign Disease: A UK Pilot Study.
    Merali N; Chouari T; Terroire J; Jessel MD; Liu DSK; Smith JH; Wooldridge T; Dhillon T; Jiménez JI; Krell J; Roberts KJ; Rockall TA; Velliou E; Sivakumar S; Giovannetti E; Demirkan A; Annels NE; Frampton AE
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pancreatic Ductal Adenocarcinoma and Nutrition: Exploring the Role of Diet and Gut Health.
    Gualtieri P; Cianci R; Frank G; Pizzocaro E; De Santis GL; Giannattasio S; Merra G; Butturini G; De Lorenzo A; Di Renzo L
    Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.